Mary Lynne Hedley, PhD
Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA
status, according to top-line results from the QUADRA study announced by TESARO, the manufacturer of the PARP inhibitor.
In the phase II open-label, single-arm study, niraparib induced an overall response rate (ORR) of 29% and a duration of response (DOR) of 9.2 months among homologous recombination deficiency (HRD)–positive, PARP inhibitor–naive, platinum-sensitive patients receiving treatment in the fourth- or fifth-line setting (n = 45).
... to read the full story